Long Non-Coding RNAs are being investigated as a potential biomarker for rare gynaecological cancers

Gynaecological cancer - Antonio Giordano

Long non-coding RNAs (lncRNAs) are detectable in body fluids like blood, saliva, and urine, and are thus emerging as a novel method for cancer diagnosis. However, few studies have looked into the link between lncRNAs and choriocarcinoma (CC), a rare but serious cancer that affects the female reproductive organs. Because early detection of CC is critical, researchers reviewed current research on lncRNAs in gestational CC and how such a connection may be used to future diagnostic tools and treatment techniques.

As part of the GYNOCARE COST Action, Antonio Giordano, M.D., Ph.D., Founder and Director of the Sbarro Health Research Organization (SHRO), co-authored the review article with 18 other co-authors from six other countries (CA18117). Prof Jean Calleja Agius, M.D., Ph.D., from the Department of Anatomy at the Faculty of Medicine and Surgery at the University of Malta, chairs GYNOCARE, a European Network for Gynaecological Rare Cancer Research: From Concept to Cure.

The work ‘An Overview of the Role of Long Non-Coding RNAs in Human Choriocarcinoma' was published in the International Journal of Molecular Sciences by Di Fiore, R et al.

In a variety of malignancies, increasing evidence suggests that lncRNAs, non-coding transcripts with more than 200 nucleotides that can serve as oncogenes or tumour suppressor genes, play a critical role.

CC is a trophoblastic disease subtype that is a relatively uncommon neoplasm with varying prevalence across the world. Approximately 1 in 40,000 pregnant women and 1 in 40 individuals with hydatidiform moles in Europe and North America will develop CC. There are two kinds of CC: gestational and non-gestational, which have quite different biological activities. In individuals with early-stage CC, a treatment strategy is extremely successful. The advanced stage of the cancer has an excellent prognosis as well, with around 95% of patients cured with treatment. Advances in diagnosis and therapy, on the other hand, are always needed to enhance outcomes for CC patients.

Dr. Antonio Giordano is the President and Founder of the Sbarro Health Research Organization (SHRO), which conducts research to diagnose, treat and cure cancer, cardiovascular disease, diabetes and other chronic illnesses.